Floatz logo

Infliximab

Anorexia

Alliance for Clinical Trials in Oncologymonoclonal_antibodyPhase 3Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Anorexia cohort.

Asset / SponsorPhaseRating
MEGESTROL ACETATE IMPURITY B
Alliance for Clinical Trials in Oncology
Phase 3BB
1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER
Mayo Clinic
Phase 3BB
Docetaxel
Alliance for Clinical Trials in Oncology
Phase 3B
Olanzapine
Alliance for Clinical Trials in Oncology
Phase 3B
Anamorelin
M.D. Anderson Cancer Center
Phase 2/3B

View all 12 →

Same molecule, other indications

Infliximab is also rated in:

CachexiaDormant
BB
Indicative ·
64 / 100
View asset →
hepatosplenic T-cell lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
colitisDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →